Back
75· Active
Health & Science1d 14h ago
The panel voted unanimously that the benefits of Eli Lilly’s experimental Alzheimer’s drug, donanemab, outweigh the risks for patients with early symptomatic disease.
Silver Spring, Maryland, U.S.
Who
FDA Peripheral and Central Nervous System Drugs Advisory Committee
What
The panel voted unanimously that the benefits of Eli Lilly’s experimental Alzheimer’s drug, donanemab, outweigh the risks for patients with early symptomatic disease.
When
Sun, 07 Jun 2026 19:50:05 GMT · 1d 14h ago
Where
Silver Spring, Maryland, U.S. · 39.0349°N, 76.9928°W
Why
Clinical trial data demonstrated a 35% slowing of cognitive decline in patients, despite concerns over potential side effects like brain swelling and bleeding.
The Frontline Impact
How this affects you
If granted final FDA approval, this will provide millions of patients a second options for anti-amyloid therapy, increasing competition and potentially lowering long-term treatment costs.
Story chain
1 event in this threadNo related history yet — this is the origin event.
Verified Sources & Citations
Credibility ratings reflect the AI ingestion pipeline's assessment of source provenance.